GAMT

Across TCGA pan-cancer cohorts, GAMT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GAMT data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GAMT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GAMT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where GAMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.979	0.420	.002	52	view →
PDAC	OS	Median	IV	0.395	0.937	.026	3	view →
HNSC	DFS	Median	III,IV	0.880	0.721	.042	3	view →
LSCC	DFS	Median	II,III,IV	0.999	0.830	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GAMT–CCRCC (DFS)

Open the CCRCC breakdown →